Evidence map›Paper›PMID 37553633›Full record

ArticleBMC complementary medicine and therapies2023

Lentinula Edodes Mycelia extract regulates the function of antigen-presenting cells to activate immune cells and prevent tumor-induced deterioration of immune function.

Shota Kajiyama, Takahiro Nagatake, Satoru Ishikawa, Koji Hosomi, Yuki Shimada, Yasunori Matsui, Jun Kunisawa

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Integrative cancer therapies
    Pooled it
  2. Review
  3. The Ethanol-Insoluble Low-Molecular-Weight Fraction LEP-4 Derived FromAdvances in pharmacological and pharmaceutical sciences · 2026
    Article
  4. Review
  5. Article
  6. Selenopolysaccharide Isolated fromInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shota KajiyamaLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki-city, Osaka, 567-0085, Japan.
Takahiro NagatakeLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki-city, Osaka, 567-0085, Japan.
Satoru IshikawaCentral R & D Laboratory, Kobayashi Pharmaceutical Co., Ltd, Ibaragi, Osaka, Japan.
Koji HosomiLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki-city, Osaka, 567-0085, Japan.
Yuki ShimadaCentral R & D Laboratory, Kobayashi Pharmaceutical Co., Ltd, Ibaragi, Osaka, Japan.
Yasunori MatsuiCentral R & D Laboratory, Kobayashi Pharmaceutical Co., Ltd, Ibaragi, Osaka, Japan.
Jun KunisawaLaboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki-city, Osaka, 567-0085, Japan. kunisawa@nibiohn.go.jp.
Kobayashi Pharmaceutical (Japan) · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPOsaka University of Pharmaceutical Sciences · JPThe University of Tokyo · JP

Funding

Japan Agency for Medical Research and Development 223fa727001h0001Ministry of Health and Welfare of Japan and Public /Private R&D Investment Strategic Expansion PrograM: PRISM 20AC5004
6 · The paper itself

Abstract

Immune cell activation is essential for cancer rejection; however, the tumor microenvironment leads to deterioration of immune function, which enables cancer cells to survive and proliferate. We previously reported that oral ingestion of Lentinula Edodes Mycelia (L.E.M.) extract enhances the tumor antigen-specific T-cell response and exerts an antitumor effect in a tumor-bearing mouse model. In this study, we focused on antigen-presenting cells (APCs) located upstream of the immune system, induced a T-cell response, then examined the impact of L.E.M. extract on the APCs. L.E.M. extract enhanced the expression of MHC-I, MHC-II, CD86, CD80, and CD40 in bone marrow-derived dendritic cells (DCs) and strongly induced the production of IL-12. L.E.M.-stimulated DCs enhanced IFN-γ production from CD8

Indexed as

NeoplasmsShiitake MushroomsAnimalsAntigen-Presenting CellsCD8-Positive T-LymphocytesImmunityInterleukin-12MiceTumor MicroenvironmentInterleukin-12Antigen-presenting cellsDendritic cellsImmunotherapyLentinula EdodesMacrophages

Identifiers

PMID37553633
PMCPMC10408224
OpenAlexW4385647605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.